Name | N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide.H2O |
---|---|
Synonyms | Ivacaftor (hydrate) |
Description | Ivacaftor hydrate is an orally bioavailable CFTR potentiator, used for cystic fibrosis treatment. |
---|---|
Related Catalog | |
In Vitro | Ivacaftor (10 µM) increases the PC secretion activity by 3-fold for ABCB4-G535D, 13.7-fold for ABCB4-G536R, 6.7-fold for ABCB4-S1076C, 9.4-fold for ABCB4-S1176L, and 5.7-fold for ABCB4-G1178S. Ivacaftor corrects the functional defect of ABCB4 mutants[1]. Ivacaftor (10 μM) significantly increases CFTR activity in W1282X-expressing cells compared to R1162X CFTR cells[2]. Ivacaftor shows no significant activity against 160 targets tested including the GABAA benzodiazepine receptor. Ivacaftor increases the chloride secretion with an EC50 of 0.236 ± 0.200 μM, a 10-fold shift in potency compared to the F508del HBEs[3]. In recombinant cells, VX-770 increases CFTR channel open probability (Po) in both the F508del processing mutation and the G551D gating mutation. VX-770 increases forskolin-stimulated IT in temperature-corrected F508del-FRT cells by appr 6-fold with an EC50 of 25 nM[4]. |
In Vivo | Ivacaftor (1-200 mg/kg, p.o.) exhibits good oral bioavailability in rat[3]. |
References |
Molecular Formula | C24H30N2O4 |
---|---|
Molecular Weight | 410.50600 |
Exact Mass | 410.22100 |
PSA | 91.42000 |
LogP | 5.08970 |
Storage condition | 2-8℃ |